Acrivon Therapeutics ACRV

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer patients. The company uses its proprietary Generative Phosphoproteomics AP3 platform to measure drug-regulated pathway activity inside intact tumor cells, enabling unbiased identification of patients likely to respond to its therapeutic candidates. This approach allows Acrivon to match its drug candidates with patients based on direct protein signaling readouts rather than genetic alterations. The AP3 platform is modality and disease agnostic, supporting the development of small molecule inhibitors across diverse oncology indications. Acrivon's pipeline includes the Lilly-licensed ACR-368, the internally discovered WEE1/PKMYT1 inhibitor ACR-2316, and a CDK11-targeted candidate ACR-6840. The company’s name, Acrivon, is derived from the Greek word for accurate or precise, reflecting its commitment to precise patient‑drug matching.

Acrivon generates revenue primarily from licensing agreements, milestone payments, and royalties associated with its in-licensed asset ACR-368 from Eli Lilly & Company. Under the Lilly agreement, Acrivon paid an upfront fee of $5.0 million and is obligated to pay aggregate development and commercial milestone payments of up to $168.0 million, with royalties ranging from low single-digits to a maximum of 10% of net sales. The company may also receive payments from collaborative arrangements, such as its former companion diagnostic agreement with Akoya, and potential future product sales upon regulatory approval of its pipeline candidates. As a pre‑revenue stage biopharma, its current income stems mainly from these contractual and partnership revenues. Should any of its pipeline candidates receive marketing approval, Acrivon expects to generate product sales revenue that would supplement its current licensing income.

Acrivon differentiates itself in the oncology precision medicine landscape by leveraging proteomic biomarkers that measure active disease‑driving pathways independent of underlying genetic mutations. This positions the company ahead of many competitors that rely solely on genomics‑based patient selection, which addresses only a small fraction of cancer patients. Key competitors include other developers of DDR and cell cycle inhibitors such as AstraZeneca, Merck, Zentalis, and Repare Therapeutics, but Acrivon believes its AP3 platform offers superior target selectivity and predictive capability. The company’s strategy emphasizes biomarker‑driven clinical trials to increase response rates and reduce development risk, a methodology not yet widely adopted by larger pharmaceutical firms. By focusing on proteomic signatures, Acrivon aims to expand the addressable patient population beyond those harboring actionable genetic alterations.

Acrivon serves patients with solid tumors of high unmet need, oncology healthcare providers, and potential pharmaceutical partners seeking licensing or collaboration opportunities. Specific counterparties named in its agreements include Eli Lilly, which licensed ACR-368, and Akoya, which previously collaborated on the ACR‑368 OncoSignature companion diagnostic. The company also works with clinical trial sites and hospitals that administer its investigational drugs to enrolled patients. Ultimately, the customers who will benefit from Acrivon’s approved therapies are the patients receiving treatment in oncology clinics and health systems worldwide.